Advertisement
JAMA Editorial Says 'Little Pink Pill' May Do More Harm Than Good
Resume
Remember the "little pink pill"? That’s the catchphrase people were using last year when there was a lot of buzz around the so-called "female Viagra." The drug — it's called Flibanserin, brand name Addyi, is supposed to increase sexual desire in women with low libidos.
It went on the market in October, but there's a new meta-analysis on the drug out in JAMA Internal Medicine, along with a biting editorial by two professors of medicine at the Dartmouth Institute.
Guest
Carey Goldberg, she runs WBUR's CommonHealth blog, which tweets @commonhealth.
More
STAT: FDA Explains Why It Approved Addyi Female Sex Pill
- "Should the Food and Drug Administration have approved the Addyi pill for female sexual dysfunction?"
Bloomberg Businessweek: The Female Libido Pill Is No Viagra
- "More than half a million men got prescriptions for Viagra in its first month on the market in 1998. The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227."
STAT: New Pill For Boosting Female Libidos Off To A Slow Start
- "The new pill for female sexual dysfunction may be one of the most talked-about new drugs of the year, but it is not getting off to such a hot start."
This segment aired on March 2, 2016.